Medicaid covers GLP-1 weight-loss drugs in just 13 states
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.
Map Shows States Where Weight Loss Drugs are Most Popular
Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed. Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite,
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid,” wrote the research team led by se
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,
States slow to cover GLP-1s for weight loss
Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive policies add to equity concerns around the blockbuster drugs,
Glucagon-like peptide-1 receptor agonists tied to lower risk for early-onset colorectal cancer
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...
Too Old to Operate7d
Glucagon-like peptide-1 receptor agonists may impact outcomes of endoscopy
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
GlobalData on MSN14h
Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Guidance issued for safe use of GLP-1 RAs in the perioperative period
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Too Old to Operate5d
Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares
The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few episodes of disease exacerbation and resulted in a significant decrease in ...
AOL22h
4 Ways to Prevent Muscle Loss on Ozempic & Other Weight Loss GLP-1 Medications
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor ...
Neurology Advisor1d
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.
GEN4d
StockWatch: Investors Hammer Lilly as GLP-1 Sales Miss Forecasts
Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...
The Motley Fool10d
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...
Renal & Urology News6d
Finerenone Added to SGLT2i + GLP1-RA Further Reduces Albuminuria in T2D With CKD
Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, ...